COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect COMPASS Pathways to post earnings of ($0.47) per share for the quarter.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
COMPASS Pathways Trading Down 6.6 %
COMPASS Pathways stock traded down $0.27 during mid-day trading on Tuesday, hitting $3.78. The company's stock had a trading volume of 449,096 shares, compared to its average volume of 1,137,778. The business has a 50 day moving average price of $3.35 and a 200-day moving average price of $4.08. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 12 month low of $2.49 and a 12 month high of $9.63. The stock has a market cap of $349.84 million, a price-to-earnings ratio of -1.72 and a beta of 2.27.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on CMPS shares. Canaccord Genuity Group dropped their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a research note on Friday, March 28th. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $20.20.
Read Our Latest Report on COMPASS Pathways
About COMPASS Pathways
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Further Reading
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
